Hosur Mahadevi B, Puranik Rudrayya S, Vanaki Shreenivas S, Puranik Surekha R, Ingaleshwar Pramod S
Department of Oral Pathology, PMNM Dental College and Hospital, Bagalkot, Karnataka, India.
Department of Oral Medicine, PMNM Dental College and Hospital, Bagalkot, Karnataka, India.
J Oral Maxillofac Pathol. 2018 May-Aug;22(2):173-179. doi: 10.4103/jomfp.JOMFP_260_17.
The central giant cell granuloma(CGCG) of bone constitutes about 10% of benign jawbone lesions. It affects females more often than males, mandible than maxilla. Biological behavior of CGCG ranges from a slow growing asymptomatic swelling to an aggressive process. True giant cell tumor (GCT) should be distinguished from CGCG. The histological distinction between these lesions depends on quite subtle differences. Expression of p63 has been demonstrated in GCT of bone conversely, has not been detected in CGCG. Therefore this short study attempts to study the expression of p63 in CGCG in conjunction with clinicopathological profile of the cases reported in the institute.
To review all the cases of CGCGs of the jaws reported in the institute from 1998 to 2015 and study their clinicopathological profile.To study the immunohistochemical (IHC) expression of p63 in CGCG cases.
The retrospective study reviewed records for clinically and histopathologically diagnosed cases of CGCG from the archives of department of Oral pathology. Data was recorded and analyzed. These cases were subjected for IHC analysis for expression of p63, also RANK, RANKL in selected cases to study the nature of giant cells.
This paper is an institutional experience of clinicopathological profile of diagnosed cases of CGCG. Clinicopathological findings were in concurrent with previous literature. Total number of cases was ten. Six occurred in females and four in males. Most of them occurred in the second decade, more commonly involving mandible. Three cases showed recurrence. Histologically most showed classical features. Expression of p63 showed negativity in all the cases in accordance with the previous studies. RANK and RANKL showed strong and diffuse immunoexpression in both mononuclear and giant cells. Thus study supports the finding that p63 expression can be used to differentiate between CGCG and GCT. However, more number of studies with larger sample size are required to confirm reliability of using p63 as a distinguishing marker between GCT and CGCG.
骨中心性巨细胞肉芽肿(CGCG)约占颌骨良性病变的10%。女性比男性更易受累,下颌骨比上颌骨更常见。CGCG的生物学行为范围从生长缓慢的无症状肿胀到侵袭性过程。真性骨巨细胞瘤(GCT)应与CGCG相鉴别。这些病变之间的组织学区分取决于相当细微的差异。p63在骨巨细胞瘤中已有表达,相反,在CGCG中未检测到。因此,这项简短的研究试图结合该研究所报告病例的临床病理特征,研究p63在CGCG中的表达。
回顾该研究所1998年至2015年报告的所有颌骨CGCG病例,并研究其临床病理特征。研究p63在CGCG病例中的免疫组化(IHC)表达。
这项回顾性研究查阅了口腔病理科档案中临床和组织病理学诊断为CGCG的病例记录。记录并分析数据。对这些病例进行p63表达的IHC分析,在部分病例中还检测RANK、RANKL,以研究巨细胞的性质。
本文是关于CGCG诊断病例临床病理特征的机构经验。临床病理结果与既往文献一致。病例总数为10例。6例发生于女性,4例发生于男性。大多数病例发生在第二个十年,更常见于下颌骨。3例出现复发。组织学上大多数表现为典型特征。与既往研究一致,p63在所有病例中均呈阴性表达。RANK和RANKL在单核细胞和巨细胞中均呈强而弥漫的免疫表达。因此,本研究支持p63表达可用于区分CGCG和GCT这一发现。然而,需要更多样本量更大的研究来证实将p63用作GCT和CGCG鉴别标志物的可靠性。